Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis

Abstract

Many human cancers have been associated with the deregulation of receptor tyrosine kinases (RTK). However, the individual contribution of receptor-associated signaling proteins in cellular transformation and metastasis is poorly understood. To examine the role of RTK activated signal transduction pathways to processes involved in cell transformation, we have exploited the oncogenic derivative of the Met RTK (Tpr–Met). Unlike other RTKs, twin tyrosine residues in the carboxy-terminal tail of the Met oncoprotein and receptor are required for all biological and transforming activities, and a mutant lacking these tyrosines is catalytically active but non transforming. Using this mutant we have inserted oligonucleotide cassettes, each encoding a binding site for a specific signaling protein derived from other RTKs. We have generated variant forms of the Tpr–Met oncoprotein with the ability to bind individually to the p85 subunit of PI3′K, PLCγ, or to the Grb2 or Shc adaptor proteins. Variants that recruit the Shc or Grb2 adaptor proteins generated foci of morphologically transformed fibroblast cells and induced anchorage-independent growth, scattering of epithelial cells and experimental metastasis. In contrast, variants that bind and activate PI3′K or PLCγ failed to generate readily detectable foci. Although cell lines expressing the PI3′K variant grew in soft-agar, these cells were non metastatic. Using this unique RTK oncoprotein model, we have established that Grb2 or Shc dependent signaling pathways are sufficient for cell transformation and metastatic spread.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

RTK:

receptor tyrosine kinase

SH2:

Src homology domain 2

PTB:

phosphotyrosine binding domain

PI3′K:

phosphatidylinositol 3′-kinase

GST:

glutathione S-transferase

PLCγ:

phospholipase Cγ

IP:

immunoprecipitation

FBS:

fetal bovine serum

References

  • Bardelli A, Basile ML, Audero E, Giordano S, Wennström S, Ménard S, Comoglio PM, Ponzetto C . 1999 Oncogene 18: 1139–1146

  • Bardelli A, Longati P, Gramaglia D, Stella MC, Comoglio PM . 1997 Oncogene 15: 3103–3111

  • Blume-Jensen P, Hunter T . 2001 Nature 411: 355–365

  • Chang J-S, Noh DY, Park IA, Kim MJ, Song H, Ryu SH, Suh P-G . 1997 Cancer Res. 57: 5465–5468

  • Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF . 1984 Nature 311: 29–33

  • Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RO, Cardiff RD, Muller WJ . 2001 Mol. Cell. Biol. 21: 1540–1551

  • Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ . 1997 Mol. Cell. Biol. 17: 5410–5425

  • DeMali KA, Whiteford CC, Ulug ET, Kazlauskas A . 1997 J. Biol. Chem. 272: 9011–9018

  • Dikic I, Batzer AG, Blaikie P, Obermeier A, Ullrich A, Schlessinger J, Margolis B . 1995 J. Biol. Chem. 270: 15125–15129

  • Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M . 1996 J. Biol. Chem. 271: 13116–13122

  • Fixman ED, Holgado-Madruga M, Nguyen L, Kamikura DM, Fournier TM, Wong AJ, Park M . 1997 J. Biol. Chem. 272: 20167–20172

  • Fixman ED, Naujokas MA, Rodrigues GA, Moran MF, Park M . 1995 Oncogene 10: 237–249

  • Fournier TM, Kamikura D, Teng K, Park M . 1996 J. Biol. Chem. 271: 22211–22217

  • Fukazawa T, Miyake S, Band V, Band H . 1996 J. Biol. Chem. 271: 14554–14559

  • Gu H, Maeda H, Moon JJ, Lord JD, Yoakim M, Nelson BH, Neel BG . 2000 Mol. Cell. Biol. 20: 7109–7120

  • Jeffers M, Koochekpour S, Fiscella M, Sathyanarayana BK, Vande Woude GF . 1998 Oncogene 17: 2691–2700

  • Jeffers M, Rong S, Vande Woude GF . 1996 J. Mol. Med. 74: 505–513

  • Jimenez C, Jones DR, Rodriguez-Vaciana P, Gonzalez-Garcia A, Leonardo E, Wennström S, von Kobbe C, Toran JL, R.-Borlado L, Calvo V, Copin SG, Albar JP, Gaspar ML, Diez E, Marcos MAR, Downward J, Martinez-A C, Merida I, Carrera AC . 1998 EMBO J. 17: 743–753

  • Kamikura DM, Khoury H, Maroun C, Naujokas MA, Park M . 2000 Mol. Cell. Biol. 20: 3482–3496

  • Kamikura DM, Naujokas MA, Park M . 1996 Biochemistry 35: 1010–1017

  • Kashishian A, Cooper JA . 1993 Mol. Cell. Biol. 4: 49–57

  • Kazlauskas A, Durden DL, Cooper JA . 1991 Cell Regul. 2: 413–425

  • Kazlauskas A, Kashishian A, Cooper JA, Valius M . 1992 Mol. Cell. Biol. 12: 2534–2544

  • Kim HK, Kim JW, Zilberstein A, Margolis B, Kim JG, Schlessinger J, Rhee SG . 1991 Cell 65: 435–441

  • Klippel A, Escobedo M-A, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM, Williams LT . 1998 Mol. Cell. Biol. 18: 5699–5711

  • Lock LS, Royal I, Naujokas MA, Park M . 2000 J. Biol. Chem. 275: 31536–31545

  • Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J . 1992 Cell 70: 431–442

  • Maroun C, Holgado-Madruga M, Royal I, Naujokas MA, Fournier TM, Wong AJ, Park M . 1999 Mol. Cell. Biol. 19: 1784–1799

  • Meakin SO, MacDonald JIS, Gryz EA, Kubu CJ, Verdi JM . 1999 J. Biol. Chem. 274: 9861–9870

  • Meisner H, Czech MP . 1995 J. Biol. Chem. 270: 25332–25335

  • Nguyen L, Holgado-Madruga M, Maroun C, Fixman ED, Kamikura D, Fournier T, Charest A, Tremblay ML, Wong AJ, Park M . 1997 J. Biol. Chem. 272: 20811–20819

  • Noh D-Y, Shin SH, Rhee SG . 1995 Biochim. Biophys. Acta 1242: 99–114

  • Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF . 1986 Cell 45: 895–904

  • Pawson T . 1995 Nature 373: 573–580

  • Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG, Comoglio PM . 1995 Oncogene 10: 1631–1638

  • Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti L, Pawson T, Pelicci PG . 1992 Cell 70: 93–104

  • Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM . 1994 Cell 77: 261–271

  • Ponzetto C, Zhen Z, Audero E, Maina F, Bardelli A, Basile ML, Giordano S, Narsimhan R, Comoglio P . 1996 J. Biol. Chem. 271: 14119–14123

  • Rodrigues GA, Naujokas MA, Park M . 1991 Mol. Cell. Biol. 11: 2962–2970

  • Rodrigues GA, Park M . 1993 Mol. Cell. Biol. 13: 6711–6722

  • Rodrigues GA, Park M . 1994 Curr. Opin. Genet. Dev. 4: 15–24

  • Royal I, Park M . 1995 J. Biol. Chem. 270: 27780–27787

  • Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG, Schlessinger J, Pawson T . 1992 Nature 360: 689–692

  • Sakaguchi K, Okabayashi Y, Kido Y, Kimura S, Matsumura Y, Inushima K, Kasuga M . 1998 Mol. Endocrinol. 12: 536–543

  • Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, Pelicci PG . 1994 Oncogene 9: 2827–2836

  • Smith MR, Court DW, Kim H-K, Park JB, Rhee SG, Rhim JS, Kung H-F . 1998 Carcinogenesis 19: 177–185

  • Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, Neel BG, Birge RB, Fajardo JE, Chou MM, Hanafusa H, Schaffhausen B, Cantley LC . 1993 Cell 72: 767–778

  • Webster MA, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton M, Tortorice CG, Cardiff RD, Graham FL, Hassell JA, Muller WJ . 1998 Mol. Cell. Biol. 18: 2344–2359

  • Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W . 1996 Nature 384: 173–176

  • Weidner KM, Sachs M, Riethmacher D, Birchmeier W . 1995 Proc. Natl. Acad. Sci. USA 92: 2597–2601

  • Zhu H, Naujokas MA, Fixman ED, Torossian K, Park M . 1994 J. Biol. Chem. 269: 29943–29948

Download references

Acknowledgements

The authors are grateful to members of the Park laboratory for critical reading of this manuscript. This work was supported by an operating grant from the Canadian Institutes of Health Research awarded to M Park, and C Saucier was supported by post-doctoral fellowships from the Royal Victoria Hospital Research Institute and Fonds de la Recherche en Sante du Quebec.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Morag Park.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saucier, C., Papavasiliou, V., Palazzo, A. et al. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene 21, 1800–1811 (2002). https://doi.org/10.1038/sj.onc.1205261

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205261

Keywords

This article is cited by

Search

Quick links